Key facts
- PolyActiva’s last known valuation is $25.8M (Jan 2012).
- It has raised $81.2M; the latest was Later Stage VC ($40.0M) in May 2025.
- Notable investors include Brandon Capital, National Reconstruction Fund Corporation, CSIRO, Bionic Ear Institute, Brandon Biocatalyst — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for PolyActiva
- ·The full record, as it builds
Funding rounds
No funding rounds for PolyActiva are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PolyActiva
Developer of drug-polymer conjugates designed for site-specific drug delivery from medical device components. The company offers a delivery platform that can carry sufficient drug products of small size and still deliver therapeutic daily doses to the therapeutic site over extended periods from implants, films, or fibers, enabling healthcare organizations to provide effective drug treatments to patients.
- Sector
- Healthcare
- HQ
- Notting Hill, Australia
- Founded
- 2010
- Employees
- 31
- Website
- polyactiva.com/
- Ownership
- Privately Held (backing)
PolyActiva doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PolyActiva shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PolyActiva in its N-PORT filings yet. We sweep new filings monthly.